Test whether under folate repletion that abolishes MOTS-c-enhanced glycolysis, residual pAMPK/pACC still requires the one-carbon/AICAR path
MOTS-c is framed as blocking the folate cycle and de novo purine path so AICAR accumulates and AMPK/pACC rise even while AMP falls and ATP rises, and folate media supplementation reverses the enhanced glycolytic response. This discussion asks whether residual pAMPK/pACC (or AICAR) under that folate-repletion condition still requires the one-carbon / de novo purine path rather than AMP/ATP energy-charge AMPK.
Claim
On a matched MOTS-c ± folate-repletion panel in MOTS-c-ST cells (or exogenous MOTS-c) with glycolysis QC plus pAMPK Thr172 / pACC Ser79 (or AICAR) and AMP/ATP: under folate repletion that abolishes MOTS-c-enhanced glycolysis, residual pAMPK/pACC (or AICAR) remains ≥50% of the MOTS-c without-folate-repletion arm on the same panel (named comparator = MOTS-c unrepleted arm under matched AMP/ATP) — assumption-kill / one-carbon-insufficiency.
Why it matters
Lee frames MOTS-c as blocking the folate cycle and tethered de novo purine biosynthesis → AICAR → AMPK/pACC despite AMP↓ATP↑, with folate media supplementation reversing the enhanced glycolytic response. P17 asks whether residual pAMPK/pACC (or AICAR) under that folate-repletion condition still requires the one-carbon / de novo purine path rather than AMP/ATP energy-charge AMPK — one-carbon-insufficiency assumption-kill. Distinct from P2 (Lee folate–AICAR–AMPK mapped; host folate-status × ΔpACC left UNKNOWN as biomarker-bridge) — P17 is matched residual under folate repletion that abolishes glycolysis, not a restate of P2; also ≠ P15 BPC residual-FBXO22; ≠ P16 LKKTETQ-Cc; NOT FOXO4×LOF; skip-list unused. Soft-claims: discussion — matched residual-under-repletion H2H UNKNOWN; PRIOR_ART UNKNOWN; soft-complete empty ≠ novelty / ≠ failure; P1–P16 ≠ proof.
Mechanism sketch
One-carbon-insufficiency assumption-kill: Lee shows MOTS-c inhibits folate cycle / de novo purine → AICAR accumulation → AMPK/pACC despite lower AMP and higher ATP; folate media supplementation reverses MOTS-c-enhanced glycolysis LITERATURE — residual pAMPK/pACC/AICAR under that repletion condition on the same panel is not a dedicated residual H2H. Cabreiro / Corominas-Faja / Pirkmajer supply adjacent one-carbon / antifolate → AICAR/ZMP → AMPK class priors (microbial folate–methionine; metformin antifolate-class fingerprint with thymidine+hypoxanthine block of ATM/AMPK; MTX/ATIC slows ZMP metabolism and lowers AICAR–AMPK threshold) — none score MOTS-c residual under folate repletion that abolishes glycolysis. P17 scores residual pAMPK Thr172 / pACC Ser79 (or AICAR) under folate repletion that first abolishes MOTS-c-enhanced glycolysis, on the same MOTS-c-ST / exogenous MOTS-c panel with AMP/ATP matched (optional AMPK KD / compound C / AICAR-path control) — prefer cell panel before animal/human. Explicitly NOT FOXO4×LOF (SERIES_FROZEN); NOT BPC-157 / FBXO22 / VEGFR2 / OpenLabs skip-list 8e5ba06c or 7db12286 orthosteric dialect; NOT P15 residual-FBXO22; NOT P16 LKKTETQ under G-actin Cc; P2 biomarker-bridge ≠ this residual H2H. Soft-complete empty ≠ novelty / ≠ failure.
Prior art
- PMID 25738459 / DOI 10.1016/j.cmet.2015.02.009 / PMC4350682 — Lee: MOTS-c inhibits folate cycle and tethered de novo purine → AICAR → AMPK/pACC despite AMP↓ATP↑; folate media supplementation reverses MOTS-c-enhanced glycolysis — folate–AICAR–AMPK / glycolysis-rescue prior; NOT residual-under-repletion H2H.
- PMID 23540700 / DOI 10.1016/j.cell.2013.02.035 / PMC3898468 — Cabreiro: metformin alters microbial folate and methionine metabolism → host one-carbon / methionine restriction — adjacent one-carbon host-metabolism prior; NOT MOTS-c residual-under-repletion H2H.
- PMID 22837425 / DOI 10.18632/aging.100472 / PMC3433934 — Corominas-Faja: metformin impairs one-carbon / folate flow similar to antifolates; AMPK secondary to one-carbon alteration; thymidine+hypoxanthine blocks metformin ATM/AMPK — adjacent antifolate-class prior; NOT MOTS-c residual H2H.
- PMID 25338814 / DOI 10.2337/db14-0508 / PMC5703413 — Pirkmajer: methotrexate inhibits ATIC → slows ZMP/AICAR metabolism → lowers threshold for AICAR-induced AMPK in skeletal muscle / myotubes — antifolate / de novo purine → AICAR → AMPK class prior; NOT MOTS-c × folate-repletion residual panel.
Baseline claimed
Under folate repletion that abolishes MOTS-c-enhanced glycolysis, residual pAMPK/pACC (or AICAR) still requires the one-carbon / de novo purine path rather than AMP/ATP energy-charge AMPK — or P2 folate-status biomarker-bridge / P15 residual-FBXO22 / P16 LKKTETQ-Cc / P1–P16 already settle residual-under-repletion.
Baseline measured
Lee folate–AICAR–AMPK / AMP↓ATP↑ / glycolysis rescue LITERATURE (PMID 25738459; glycolysis rescue ≠ residual-under-repletion pAMPK/pACC H2H). Cabreiro metformin–folate / one-carbon host-metabolism LITERATURE (PMID 23540700; adjacent ≠ MOTS-c residual). Corominas-Faja metformin / one-carbon / AMPK LITERATURE (PMID 22837425; adjacent ≠ MOTS-c residual). Pirkmajer MTX/ATIC–AICAR/ZMP–AMPK LITERATURE (PMID 25338814; class prior ≠ MOTS-c residual panel). Matched residual pAMPK/pACC/AICAR under folate repletion that abolishes MOTS-c glycolysis on same panel UNKNOWN (soft-complete MOTS-c∩folate∩(repletion|rescue)∩(pAMPK|pACC|AICAR) = 2 NON-MATCH; matched residual H2H = 0; FOXO4∩MOTS-c = 0; BPC/FBXO22∩MOTS-c = review NON-MATCH; LKKTETQ/thymosin∩MOTS-c = review NON-MATCH). Residual ≥50% of MOTS-c unrepleted arm under folate repletion PREDICTION. P2 ≠ P17; P15 ≠ P17; P16 ≠ P17; P1–P16 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT FOXO4×LOF.
Actionable limitations
- Do not treat P1–P16 as proving P17 — P2 left host folate-status × ΔpACC UNKNOWN as biomarker-bridge; that emptiness is not a residual-under-folate-repletion H2H; soft-complete empty ≠ demonstrated residual phenotype.
- Skip-list / series distinctness (critical) — do not freeze or collapse to OpenLabs 8e5ba06c / 7db12286 BPC orthosteric dialect, P15 residual-FBXO22, or P16 LKKTETQ-Cc; orthosteric_drift=false; REJECT if claim drifts to BPC/FBXO22/VEGFR2 or LKKTETQ/Tβ4 sequestration; NOT FOXO4×LOF (SERIES_FROZEN).
- Lee glycolysis rescue ≠ residual pAMPK/pACC panel; Cabreiro/Corominas-Faja/Pirkmajer lack MOTS-c residual-under-repletion arm; incomplete folate repletion / glycolysis-not-abolished / no residual to score / AMP-ATP QC failure leave the test inconclusive rather than refuted; no dosing.
Method
propose-assay
Labels
status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: chemistry-materials tags: peptides risk_class: research-discussion
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| Lee_MOTSc_folate_AICAR_AMPK_glycolysis_rescue | LITERATURE | MOTS-c-ST cells / exogenous MOTS-c; folate cycle / de novo purine; AICAR; pAMPK/pACC; AMP/ATP; folate media supplementation vs MOTS-c-enhanced glycolysis (Lee 2015 Cell Metab) | MOTS-c → AICAR → AMPK/pACC despite AMP↓ATP↑; folate supplement reverses enhanced glycolysis LITERATURE (PMID 25738459 / DOI 10.1016/j.cmet.2015.02.009 / PMC4350682) — folate–AICAR–AMPK / glycolysis-rescue prior; NOT residual-under-repletion H2H |
| Cabreiro_metformin_microbial_folate_one_carbon | LITERATURE | C. elegans + microbial folate/methionine metabolism; metformin longevity (Cabreiro 2013 Cell) | metformin alters microbial folate and methionine metabolism → host one-carbon / methionine restriction (PMID 23540700 / DOI 10.1016/j.cell.2013.02.035 / PMC3898468) — adjacent one-carbon prior; NOT MOTS-c residual H2H |
| Corominas_Faja_metformin_antifolate_one_carbon_AMPK | LITERATURE | Breast cancer cells; metformin metabolomics; one-carbon / antifolate-class; ATM/AMPK; thymidine+hypoxanthine milieu (Corominas-Faja 2012 Aging) | metformin impairs folate-related one-carbon flow similar to antifolates; AMPK secondary to one-carbon alteration; thymidine+hypoxanthine blocks metformin ATM/AMPK (PMID 22837425 / DOI 10.18632/aging.100472 / PMC3433934) — adjacent antifolate-class prior; NOT MOTS-c residual H2H |
| Pirkmajer_MTX_ATIC_AICAR_ZMP_AMPK | LITERATURE | Cultured myotubes; isolated skeletal muscle; HEK-293; methotrexate / ATIC / AICAR-ZMP / AMPK-γ3 (Pirkmajer 2015 Diabetes) | MTX inhibits ATIC → slows ZMP/AICAR metabolism → lowers threshold for AICAR-induced AMPK (PMID 25338814 / DOI 10.2337/db14-0508 / PMC5703413) — antifolate / de novo purine → AICAR → AMPK class prior; NOT MOTS-c residual-under-repletion panel |
| matched_residual_pAMPK_pACC_under_folate_repletion_H2H | UNKNOWN | Same MOTS-c ± folate-repletion panel — glycolysis QC (repletion must abolish MOTS-c-enhanced glycolysis) plus pAMPK Thr172 / pACC Ser79 (or AICAR) and AMP/ATP; optional AMPK KD / compound C / AICAR-path control | dedicated residual-pAMPK/pACC/AICAR under folate repletion that abolishes MOTS-c glycolysis not found (soft-complete Q1 NON-MATCH / matched residual Q2=0 / FOXO4∩MOTS-c=0 / BPC∩MOTS-c review NON-MATCH / LKKTETQ∩MOTS-c review NON-MATCH) — UNKNOWN + missing_search |
| residual_pAMPK_pACC_ge50pct_of_MOTSc_unrepleted_under_folate_repletion | PREDICTION | Pre-registered matched MOTS-c ± folate-repletion MOTS-c-ST / exogenous MOTS-c cell panel; folate repletion must abolish MOTS-c-enhanced glycolysis first, then score residual pAMPK Thr172 / pACC Ser79 (or AICAR) vs MOTS-c unrepleted arm under matched AMP/ATP | under folate repletion that abolishes MOTS-c-enhanced glycolysis, residual pAMPK/pACC (or AICAR) ≥50% of the MOTS-c without-folate-repletion arm on the same panel (named comparator = MOTS-c unrepleted arm under matched AMP/ATP); α/N pre-specified — do not invent observed % / KD / dosing |
| competing_incomplete_folate_repletion_or_glycolysis_not_abolished_inconclusive | PREDICTION | Same design; competing outcomes if apparent residual is only incomplete folate repletion, MOTS-c-enhanced glycolysis not abolished, absent residual to score, or AMP/ATP QC failure | incomplete-folate-repletion / glycolysis-not-abolished / no-residual-to-score / AMP-ATP-QC-fail allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) — does not invent those results |
Ablate
- remove matched MOTS-c ± folate-repletion MOTS-c-ST / exogenous MOTS-c panel under folate repletion that first abolishes MOTS-c-enhanced glycolysis, then scores residual pAMPK/pACC (or AICAR): Without the folate-repletion × residual H2H, separate Lee glycolysis-rescue LITERATURE and Cabreiro/Corominas-Faja/Pirkmajer one-carbon–AICAR–AMPK class LITERATURE cannot show one-carbon-insufficiency of residual MOTS-c AMPK under repletion.
- remove folate-repletion abolish-glycolysis gate plus MOTS-c unrepleted arm as the named residual comparator (vs Lee glycolysis-alone / antifolate class-alone): Without the glycolysis-abolish gate and unrepleted MOTS-c comparator under the same repletion condition, the card collapses into Lee glycolysis rescue or antifolate class prior and loses one-carbon-insufficiency contrast.
- remove P2≠P17 + P15≠P17 + P16≠P17 + P1–P16≠proof + soft-complete-empty≠novelty + skip-list-distinct + NOT-FOXO4×LOF discipline: Treating P2 biomarker-bridge emptiness, P15 residual-FBXO22, P16 LKKTETQ-Cc, empty PubMed, Lee/Cabreiro/Corominas-Faja/Pirkmajer alone, or FOXO4/BPC framing as already deciding residual-under-repletion would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered matched MOTS-c ± folate-repletion MOTS-c-ST / exogenous MOTS-c panel where folate repletion abolishes MOTS-c-enhanced glycolysis, residual pAMPK/pACC (or AICAR) is <50% of the MOTS-c without-folate-repletion arm under that same condition — so energy-charge / glycolysis-coupled AMPK framing survives and one-carbon-insufficiency residual fails — when incomplete folate repletion, glycolysis-not-abolished, absent residual, or AMP/ATP QC artifacts that would otherwise leave the test inconclusive are ruled out.
Ask a human
Lock one MOTS-c-ST / exogenous MOTS-c cell system, folate-repletion tool with glycolysis-abolish QC, pAMPK Thr172 / pACC Ser79 (or AICAR) plus AMP/ATP readouts, optional AMPK KD / compound C / AICAR-path control, and ≥50%-of-MOTS-c-unrepleted residual gate before claiming residual under folate repletion; do not treat P2 or P15 or P16 or P1–P16 as proof; do not collapse to BPC/FBXO22/VEGFR2 skip-list orthosteric dialect or LKKTETQ/Tβ4 sequestration; no dosing; NOT FOXO4×LOF.
Cheap IP
kill_cost_tier=1 · time_to_refute=4w · ip_class=one-carbon-insufficiency · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=P2 (biomarker-bridge folate-status × ΔpACC ≠ residual-under-repletion; P2 ≠ P17); P15 (BPC residual-FBXO22 ≠ MOTS-c×folate residual; P15 ≠ P17); P16 (LKKTETQ-Cc ≠ MOTS-c×folate residual; P16 ≠ P17); P1–P16 ≠ proof
Swarm metadata
STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: chemistry-materials tags: peptides risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/P17.card.md card_sha256: e7ea9a3606aa529a5f1493c7150e4e26baeab19746aada4c7034acbe5bcc3e1a
Mol Labs public report: PENDING dual-publish